Navigation Links
Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 17, 2007 - Curis, Inc. (NASDAQ:CRIS), a drug development company focused on novel targeted medicines primarily for cancer treatment, today announced that its data was included in two presentations at the 98th Annual Meeting of the American Association for Cancer Research (AACR).

At AACR, Curis also disclosed that its April 2005 discovery collaboration agreement with Genentech focused on developing drug candidates that target the Wnt signaling pathway, particularly for potential cancer indications. Abnormal activation of Wnt signaling is present in various cancers, including colon, breast and ovarian cancers. Developing drug candidates that are designed to inhibit, or antagonize, Wnt signaling could hopefully provide a potential option in certain cancers.

On April 14, data was presented during an Educational Session titled "Targeting the Wnt Pathway in Cancer," which included a discussion of the Curis-Genentech joint effort in the identification of small molecule inhibitors of the Wnt pathway, under the April 2005 discovery collaboration agreement. The parties' research efforts have yielded a class of Wnt antagonists that, in preclinical studies, inhibit the Wnt pathway by acting upstream of beta-catenin, which is believed to be an important molecular target in the Wnt pathway. Inhibiting such an upstream molecular target may represent an attractive approach for potential inhibition of the Wnt pathway in cancer cells with abnormally active Wnt signaling.

In addition to the Educational Session, a poster was also presented at the conference describing the use of Hedgehog antagonists in a preclinical pancreatic tumor model. In these studies, Genentech and Curis scientists used a potent small molecule antagonist of the Hedgehog pathway on mice implanted with primary human pancreatic cancer xenografts. The scientists found that antagonizing the Hedgehog pathway res
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:5/29/2015)...  Dr. Yair Walzer has added a leading ... often caused by menopause. The MonaLisa Touch™, an in-office procedure ... clearance in 2014. Dr. Walzer is one of the first ... special fractional CO 2 laser specifically designed to help ... In 2010 there were greater than 46M women between ...
(Date:5/29/2015)... 2015 LifeNet Health plans to enlarge its ... to more than 160 people. The organization,s ... Health,s innovative bio-implants, which are being made more widely ... served. It also is a reflection of the region,s ... growth and success of LifeNet Health is a great ...
(Date:5/29/2015)... and MENLO PARK, Calif. ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and ... and commercializing proven cancer therapies in new orphan ... American Association of Cancer Research (AACR) Advances ... potential for its lead product candidate VAL-083 ...
Breaking Medicine Technology:The Newest FDA-Cleared Breakthrough In Women's Health Treatments 2LifeNet Health to add more than 160 jobs in 2015 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5
... 6, 2010 The Novartis Pharmaceutical Corporation ("Novartis") ... control and tumor reduction in extensively pretreated Hodgkin ... refractory after an autologous stem cell transplant, according ... trial presented today(1). In this pivotal ...
... 2010 Direct Relief International announced ... medical supplies to assist cholera patients in Haiti. The products ... JUH is the main public hospital for the entire northern ... also be distributed to the numerous cholera treatment units (CTUs) ...
Cached Medicine Technology:Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 2Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 3Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 4Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 5Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 6Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 7CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti 2CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti 3
(Date:5/29/2015)... NY (PRWEB) May 29, 2015 The ... as well as a number of specific concerns within, ... stigma reduction and mental health in the workplace. We ... mental health. The campaign also brings special focus to ... individuals to speak up and seek help from healthcare ...
(Date:5/29/2015)... Ca (PRWEB) May 29, 2015 ... pain consultations with specialists, physical therapy, and injections ... experiencing mid back and/or lower back pain, Healthpointe ... epidural injections for herniated discs, disc protrusions and ... . , Healthpointe’s team of renowned surgeons ...
(Date:5/29/2015)... 2015 The Global Allopurinol Industry ... on the current state of the Allopurinol industry.With ... statistics on the state of the industry and ... for companies and individuals interested in the market. ... industry including definitions, classifications, applications and industry chain ...
(Date:5/29/2015)... Florida (PRWEB) May 29, 2015 Designed ... Bodybuilding.com teamed up to create an all new, exclusive ... are a formulated with the latest and greatest, high ... and proven to be effective. The 24/7 Series can ... to cross-fitters and even the casual fitness enthusiasts. There ...
(Date:5/29/2015)... Javlin continues to fulfill its worldwide growth ... larger team, with the intention to better serve the ... the U.S. and Canada. , Javlin Inc., the wholly ... in 2014 with its strongest earnings to date, based ... CloverETL. To accelerate further progress and ensure exceptional customer ...
Breaking Medicine News(10 mins):Health News:Mediaplanet Brings Activism to Those Living with Mental Illness in Bew “Mental Health Awareness” Campaign 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3Health News:Allopurinol Industry (Global, China) 2015 Research Analysis and 2020 Forecasts 2Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 2Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 3Health News:Growth of Data Integration Platform CloverETL Continues in North America 2
... Workers Seeking Ground Rules for Union Election Say Hospital System Fails ... ... 27 Hundreds of faith leaders,elected officials and other community members ... and procession outside the,system,s headquarters on Saturday, where they called for ...
... Discussed at American Society of Plastic Surgeons Annual ... ... fact or fiction, non- and minimally-invasive techniques to,remove fat are making headlines. ... surgery? Plastic surgeons will discuss if,these are cutting edge new discoveries or ...
... 27 The American Red Cross,Blood Services national system ... into southern California to help stabilize the blood,supply in ... Red Cross has provided nearly 2,000 blood products to ... Blood Services Region.,Blood drives in southern California have been ...
... 8 and 9, 2007, PENSACOLA, Fla., Oct. ... to be a major sponsor for this Summit. ... in,healthcare, the Department of Defense, Veterans Administration, research,organizations ... solutions,for strategic health intelligence. This summit represents the ...
... WITH ... , http://www.mccormickandschmicks.com/index.cfm?fuseaction=content.display Adult-Care.Org, Inc. ... to promote Better Choice, Healthy Food and a Healthy ... reach a new generation of consumers., PORTLAND, Ore., Oct. ...
... of Estrostep Fe Under TriLegest(TM) Fe ... ... Barr,Pharmaceuticals, Inc. (NYSE: BRL ) today announced that its subsidiary, ... (FDA) for its Abbreviated New Drug Application (ANDA) to,manufacture and market ...
Cached Medicine News:Health News:Healthcare Workers to St. Joseph Health System: Fair Election Agreement Now 2Health News:Non-Invasive Fat-Melting Procedures - Hype or Reality? 2Health News:American Red Cross Blood Services Supports Blood Needs of Southern California 2Health News:Cogon Systems Supports the Pensacola Bay Area Chamber of Commerce with the Strategic Health Intelligence Summit 2Health News:Barr's Generic Version of Estrostep(R) Fe Tablets Approved 2Health News:Barr's Generic Version of Estrostep(R) Fe Tablets Approved 3Health News:Barr's Generic Version of Estrostep(R) Fe Tablets Approved 4
... aluminum cuffs that can be bent to ... joint alignment, unique slot/screw adjustment mechanism allows ... cuff position. Cuffs are configured to offer ... with contractures.,The hinge can be locked in ...
... Elbow Wrap replaces messy taping and bulky ... others experiencing epicondylitis. Preferred by doctors and ... fit. Two overlay straps allow you to ... lining holds the Elbow Wrap comfortably in ...
... The Bledsoe Original Arm Brace is ... elbow strains and ligament trauma. The Bledsoe ... limited R.O.M. or locked control of the ... Bledsoe Extender Arm Brace can be formed, ...
... lightweight brace allows it to fit easily into ... joint following severe sprains, tendonitis or after cast ... with the ankle and provide optimum medial-lateral support. ... rotational strains on the ankle, and they provide ...
Medicine Products: